
ABSTRACT Objectives Renal transplant recipients (RTRs) are at increased risk of keratinocyte cancer (KC) development due to immunosuppression. A single‐centre retrospective cohort study was conducted to determine the incidence, risk factors and impact on mortality of KCs in RTRs. Methods All RTRs attending an adult transplant dermatology service in Victoria, Australia between 1 January 2004 and 1 March 2020 were included. Age, gender, age at transplantation and immunosuppression regimen were recorded at baseline. At each encounter, a whole body examination was performed, and histologically confirmed KCs were recorded. Linkage was performed with the Australia and New Zealand Dialysis and Transplant Registry to obtain mortality data. Results Of the 414 participants, 162 (39%) were diagnosed with a KC (basal cell carcinoma [BCC], invasive squamous cell carcinoma [SCC], or squamous cell carcinoma in situ [SCCis]). A total of 1110 KCs were diagnosed. Of these, 451 (40.63%) were invasive SCC, 341 (30.72%) were BCC and 318 (28.65%) were SCCis. Risk factors for KC included skin phototype 1 or 2, exposure to mycophenolate (aHR 2.19, CI 1.39–3.46, p = 0.001), male gender (aHR 1.84, CI 1.27–2.68, p = 0.01), older age (aHR 1.28, CI 1.19–1.38, p < 0.001) and longer transplant duration (aHR 1.15, CI 1.04–1.28, p = 0.005). Eighty‐two (19.8%) patients died, most commonly of malignancy ( n = 21, 25.6%). Diagnosis of invasive SCC was associated with mortality in univariate analysis (HR 2.85; 95% CI, 1.82–4.46 p < 0.001) but narrowly failed to reach significance on multivariable analysis (HR 1.59, CI 0.92–2.76, p = 0.098). Conclusions These findings highlight the burden of KC‐related morbidity and mortality in RTRs. Vigilant monitoring is of vital importance in this population.
ABSTRACT Kava ( piper methysticum ) is a traditional beverage of Pacific Island communities which in 2021, re‐entered the Australian market, primarily promoted as an anxiolytic ‘wellness’ product. Emerging cases of acute kava toxicity have occurred since, characterised by a distinctive cutaneous morphology, with or without systemic manifestations. We present a multicentre case series of acute kava toxicity from South Australia and review the proposed mechanisms of toxicity, clinical presentation, distinct histopathology and implications for clinical practice.
The consensus-based guideline developed under the auspices of the German Der-matological Society (DDG) is intended to provide physicians with a structured framework for clinical decision-making in the management of patients with tinea capitis and to contribute to improved diagnostic accuracy, treatment adherence, and prevention. Tinea capitis is a dermatophyte-induced infection of the scalp that predominantly affects children and represents a common dermatological condition worldwide. In recent years, a marked shift in the epidemiology of causative dermatophytes has been observed in Europe, driven by migration, tourism, and socioecono-mic factors, with an increasing prevalence of anthropophilic species, particularly Trichophyton tonsurans and Trichophyton violaceum. From a therapeutic perspective, a combination of systemic and topical antifun-gal treatment is recommended, as topical monotherapy is generally insufficient. In pediatric patients, the choice of systemic antifungal therapy is primarily gui-ded by the identified pathogen, with Trichophyton infections preferably treated with terbinafine (off-label) and Microsporum/Nannizzia infections with itracona-zole (off-label) or griseofulvin. In adult patients, terbinafine is recommended as first-line therapy irrespective of the causative species. In addition, the guideline addresses measures to interrupt chains of infection, including the treatment of asymptomatic carriers, implementation of hygiene measures, and management of outbreak situations in community settings